Skip Navigation
Toggle Navigation
Search:
Search Submit
About
Our Company
Executive Team
Partners
Our Culture
Programs
Pipeline
Scientific Presentations
Clinical Trials
Expanded Access Policy
News
Press Releases
Careers
Who We Are
Job Opportunities
Contact Us
Programs
Clinical Trials
Furmonertinib
FURVENT
FURMO-004
First-line Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
FURMO-002
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With Activating EGFR or HER2 Mutations
For more information about furmonertinib clinical studies:
628-277-4836
FURMO@
null
arrivent.com